New Analysis Confirms Carfilzomib Survival Benefit in Relapsed/Refractory Myeloma

Published: Wednesday, Dec 13, 2017

Hypertension (17.1% vs 8.7%) and venous thrombotic events (10.2% vs 6.2%) occurred more often with carfilzomib. Otherwise, the incidence of acute renal failure, cardiac failure, ischemic heart disease, and peripheral neuropathy occurred in a similar proportion of patients in both groups. The most common grade ≥3 special interest AE was hypertension (6.4% with carfilzomib). No other grade ≥3 special-interest event occurred in as many as 5% of patients.

“The safety is consistent with previous findings, and no new safety signals were observed for carfilzomib, lenalidomide, and dexamethasone after extended follow-up,” said Stewart.


  1. Stewart AK, Siegel D, Ludwig H, et al. Overall survival (OS) of patients with relapsed/refractory multiple myeloma (RRMM) treated with carfilzomib, lenalidomide, and dexamethasone (Krd) versus lenalidomide and dexamethasone (Rd): Final analysis from the randomized phase 3 ASPIRE trial. Presented at: American Society of Hematology 59th Annual meeting; December 9-12, 2017; Atlanta, GA. Abstract 743.
  2. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372:142-152.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication